Breaking AI & Tech News Analyzed

England's women's football team is on a roll, maintaining a 100% record in their World Cup qualifying group after a win against Spain. While their target is to win a first world title, the journey is long, and several players have enhanced their prospects of selection. Eight players from the recent match against Spain look set to be in the first-choice XI for the World Cup, including Hannah Hampton, Lucy Bronze, and Lauren Hemp. Senior players like Leah Williamson and Ella Toone will also be key when they return from injuries. Three players who started against Spain have significantly boosted their chances. Centre-backs Esme Morgan and Lotte Wubben-Moy were exemplary, helping England keep a clean sheet against the world champions. Morgan, 25, and Wubben-Moy, 27, have had to be patient during Sarina Wiegman's tenure but did not look out of place. Morgan said she was proud of the team's concentration and organisation, while Wiegman praised them, saying, 'They showed up today. It says a lot about them. They should be proud of themselves.' Another player who impressed was Lucia Kendall, the 21-year-old Aston Villa midfielder tasked with taking on Barcelona's Patricia Guijarro. Despite a quiet evening, Kendall worked hard and nearly scored from close range. Wiegman also displayed trust in Laura Blindkilde Brown, who came on as a 72nd-minute substitute to help close out the victory. Her contributions to Manchester City's likely title success will enhance her chances for 2027. The upcoming match against Iceland will provide further opportunities for players like Jess Park, who has been in inspired form for Manchester United. New faces Erica Meg Parkinson and Keira Barry have received their first senior call-ups and will look to make an impression.

A recent set of studies has brought to light a concerning issue in social science research: up to half of all results published in reputable journals cannot be replicated by independent analysis. This problem is part of a broader challenge affecting various research fields, most notably social sciences and psychology, though concerns have also been raised in areas of biomedical research. The latest work, part of a seven-year project called Systematizing Confidence in Open Research and Evidence (Score), analyzed 3,900 social science papers. It found that newer papers and those published in journals requiring extensive sharing of underlying data were more likely to be reproduced. Additionally, medical research faces its own set of constraints, such as differing patient caseloads and limited sample sizes, which can make it resemble social sciences more than laboratory physics. Policymakers should be cautious of claims that don’t have a wide and robust base of evidence. The issue of reproducibility is crucial, as it looks at whether results can be recreated from the same data and methods, while replication tests whether the finding holds for new data in different contexts. However, politicians have increasingly looked to turn uncertainty into denial and recast normal scientific uncertainty as evidence of failure. Large-scale verification projects, like those undertaken by Score, are few and far between. Most academic researchers prioritize work that is more likely to enhance their careers. AI may help in deciding what to test, but it can’t reduce the costs and time involved in duplicating a piece of research. Not every failed replication signals a crisis; some findings don’t matter much, and replication studies can themselves be flawed. Greater transparency makes outright fraud more difficult and allows errors to be identified. Some argue that research “ultimately autocorrects,” but the long-term solution — shifting incentives so existing results are tested — would increase confidence. This requires restructuring of research culture and funding. For now, it remains largely notional. These studies should strengthen the case for change and serve as a warning. Social science is a powerful tool for understanding the world – and that trust will be built by acknowledging uncertainty, not repudiating it.

On O’Connell Street, a lime‑green CLAAS tractor arrived with a 19‑year‑old driver named Dylan, who explained that his convoy was the second to join a city‑wide fuel blockade that halted traffic for nearly a week. The protest, organized by farmers, hauliers and fishermen, highlighted the impact of a 60% increase in fuel duties and taxes on everyday Irish life. Dylan warned that the surge in fuel costs would eventually ripple through food prices, threatening household budgets across the nation. He and his companions, two teenagers, had endured cold nights inside the tractor, underscoring the desperation felt by many workers. The unrest, described by the Irish president as an "illegal war on Iran," has laid bare Ireland’s dependence on fossil fuels and the lack of a coherent transition strategy toward renewable energy. During six days of action, protestors blocked motorways, ports, the country’s sole oil refinery in County Cork, and fuel depots in Limerick and Galway. By the end of the week, petrol stations began to run low, prompting the justice minister to consider deploying the army. Yet on the streets, public sentiment was largely supportive; a recent poll indicated that 56% of respondents backed the demonstrators. Historical symbolism filled the scene: tractors flew the Irish tricolour beside buildings still scarred by the 1916 Easter Rising, while a lorry bore a painted coffin with the words "RIP Ireland" and a banner reading "Easter 2026". Critics on national radio questioned the tactics, citing concerns for vulnerable patients unable to reach medical appointments. Nonetheless, the direct‑action approach succeeded in drawing international attention and pressuring the government. When mounted police units arrived on Sunday morning, the convoy withdrew peacefully. Shortly thereafter, the coalition of Fianna Fáil and Fine Gael announced a €500 million concession package, augmenting an earlier €250 million relief plan with cuts to excise duty and a postponement of the next carbon‑tax increase. Despite the financial concessions, a looming no‑confidence vote appears unlikely to topple the centre‑right coalition, even as public trust in traditional parties wanes. Dylan, too young to have voted in the last election, expressed little confidence in the political establishment. The protests have also been infiltrated by far‑right elements, with some speakers promoting anti‑immigrant conspiracies and misogynistic rhetoric. One spokesperson was found to have prior convictions for animal cruelty, and the Muslim Sisters of Éire reported being told to "go home" by flag‑waving agitators, highlighting a surge in xenophobic discourse. Beyond the immediate fuel price surge—up roughly 20% in a single month—the demonstrations raise broader questions about Ireland’s reliance on volatile global markets. The nation imports over 80% of its fruit and vegetables, while its data‑centre sector now consumes more electricity than all urban households combined, underscoring the tension between economic growth and sustainable energy policy. Analysts argue that lasting change cannot be achieved by pushing working people to the brink while catering to corporate interests. Ireland is expected to lobby the EU for a pause on carbon‑tax increases and to join calls for an EU‑wide tax on oil and gas profits, similar to measures advocated by Spain. In sum, the Dublin fuel blockade has forced the government to concede significant fiscal relief, exposed deep structural vulnerabilities in Ireland’s energy and food supply chains, and sparked a contentious debate over the role of grassroots protest, social cohesion, and climate justice.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

Malina Lee, a 31‑year‑old wedding baker from San Antonio, joined TikTok in 2020 to pass the lockdown‑induced boredom and promote her business. Four years later, an anonymous commenter called “PickleFart” noticed an asymmetrical neck in one of her videos and suggested she check for a goiter.The tip proved accurate: doctors confirmed thyroid cancer. Lee received prompt treatment and, within a year, was declared cancer‑free. She told the outlet that her oncologist was amazed at how early the disease was caught, crediting the TikTok comment as the catalyst.Lee’s experience is part of a growing trend where TikTok’s hyper‑targeted algorithm surfaces health‑related content that resonates with users’ unnoticed symptoms. In several cases, community members have flagged potential conditions that clinicians initially missed.The “PickleFart” persona belongs to Billie Jean Tuomi, who calls herself the “thyroid avenger.” A thyroid‑cancer survivor herself (diagnosed in 2012), Tuomi now scans videos for neck asymmetry and gently advises creators to seek a thyroid panel—a blood test measuring hormone levels and antibodies. The American Thyroid Association recommends adults start routine thyroid testing at age 35, or annually for high‑risk individuals.Tuomi estimates she has flagged dozens of videos, with at least four confirmed serious thyroid issues, including Lee’s. She stresses she does not claim to diagnose, merely urges viewers to consult a physician. After a viral comment, she received a flood of private messages with neck photos, prompting her to change her username.Lee, inspired by Tuomi’s intervention, has begun commenting on other users’ videos, helping one individual discover an enlarged thyroid that required removal. She describes the process as a “domino effect” of community‑driven health awareness.Medical professionals acknowledge the double‑edged nature of this phenomenon. Craig Mittleman, director of emergency services at Lawrence + Memorial Hospital, notes a rise in patients arriving with self‑diagnoses sourced from social media. While this can empower patients to ask informed questions, it also burdens clinicians with debunking misinformation.Gender disparities amplify the issue: research shows women are more likely to seek health information online, often after feeling dismissed by traditional providers. TikTok user Tori Mosser, a 23‑year‑old filmmaker, credits a direct message suggesting chronic appendicitis for prompting surgery that resolved her chronic vomiting episodes.Both Lee and Mosser emphasize the therapeutic value of finding a supportive community on TikTok, especially for invisible or chronic illnesses that are frequently minimized in clinical settings.

Rehab did not happen to Lena Dunham; she walked into it. The writer describes the moment she entered a stone‑manor facility in the Berkshires, Massachusetts, and was immediately asked to remove her designer shoes and answer mundane questions about her diet, a surreal welcome that felt like a college orientation—except many of the fellow residents struggled with IV heroin. She notes the unsettling blend of patients and staff, all dressed in ordinary clothes, making it impossible to tell who was who. A tattooed man in a Harley‑Davidson shirt turned out to be a sober companion, while a grandmother knitting in slippers battled a severe Benadryl addiction that had once ruined her daughter’s wedding. “Never judge a drug addict by their Patagonia half‑zip fleece,” she writes. Using the pseudonym “Rose O’Neill” – after the pioneering cartoonist – Dunham reflects on feeling trapped in a cycle reminiscent of the late‑career decline of the early 20th‑century artist. It was only after she allowed staff to use her real name that she began to reclaim her identity. Her therapist, Dr. Mark, a kindly man in khakis, asked her to articulate the root causes of her admission. Dunham linked her descent to chronic physical illness, relentless stress from supporting multiple families, hormonal turmoil after a hysterectomy, and a fraught romantic relationship. She also disclosed past sexual trauma, describing the rehab experience as “a fever dream” that echoed those memories. Medication played a paradoxical role. While Klonopin eased anxiety and Percocet dulled pain, the initial IV dose produced a euphoric “shiver through the whole body, better than any orgasm.” She acknowledges the temporary relief as a “pause button” that allowed her racing thoughts to quiet, yet also recognized the danger of dependence. Group sessions revealed complex dynamics. A fellow patient, Walter, breached confidentiality, prompting staff to enforce policy and send him home. The ensuing discussion divided the group, with some defending Walter’s lapse and others demanding accountability. Dunham’s own voice was subdued, emphasizing the tension between personal safety and collective responsibility. In a values‑mapping exercise, Dunham listed ART, FAMILY, MAKING PEOPLE FEEL SEEN as her core priorities, contrasting them with the values of the people she had surrounded herself with during active addiction. This exercise highlighted the stark misalignment between her aspirations and the environment she had inhabited. Despite the strict regimen, Dunham was granted a brief leave to attend the 2018 Met Gala. The decision sparked intense debate among staff about safety, yet she ultimately walked the red carpet, feeling “wan and haunted” amid flashing cameras and champagne she could not enjoy. The experience underscored the surreal juxtaposition of celebrity life and rehab recovery. During the final week, she formally identified as an addict and faced the pivotal question from Dr. Mark: “Do you want to be sober?” The answer marked a turning point, culminating in a moment of pure joy as she ran outdoors, feeling her legs move of their own accord. She closes with a vivid scene of spotting a robin’s egg on the grass, a simple yet profound reminder of life’s unexpected beauty. The memoir Famesick, published by Fourth Estate on 14 April, expands on these revelations and invites readers into the often‑hidden world of addiction behind the celebrity façade.